MAP produces a series of podcasts exploring the evolving market access processes and latest updates on MAP Online, created with the vision to revolutionise the way market access information is provided.
February 2019 newsletter podcast
In our February podcast, we discussed some recent Brexit news, and Dame Sally Davies’ move to the University of Cambridge. We also launched MAP’s report Access to Orphan Medicines: A Case for Change and previewed some upcoming pages and content.
January 2019 newsletter podcast
In the first podcast of 2019, we talked about the Falsified Medicines Directive, the NHS Long-Term Plan, and Vaccines in Germany. We also previewed some of the content currently in development for MAP Online.
December 2018 newsletter podcast
In the final podcast of 2018, we discussed the reformed Voluntary Scheme and Statutory Scheme for pharmaceutical pricing in the UK (replacing PPRS and the Statutory Regulations). We also discussed NICE proposing to charge for health technology appraisals from April, and pointed users to a refresh of our content on the Accelerated Access Collaborative.
November 2018 newsletter podcast
This edition of the podcast recapped a successful conference season for MAP. We held our own Patient Access Europe event in Brussels, and sent a large delegation to ISPOR Europe in Barcelona. We presented a number of posters there, showcasing our research capabilities. We discussed what’s known so far about the new iteration of PPRS and talked through other big news stories, and we covered the launch of our revamped CE-marking pages on our MedTech site. Our ATMP and Biosimilars pages have also been updated.
October 2018 newsletter podcast
In October we first remind our listeners of the upcoming MAP Conference. We then discuss how we have been developing MAP online content regarding early access schemes in European countries and adding updates on the UK Advanced Therapy Medicinal Products (ATMPs) page. The podcast continues with a round up of the news stories regarding Brexit and the reduction in numbers of both UK-based clinical trials and patents being filed for point-of-care medtech devices. Finally, a reminder was given of what MAP Online does for our members.
September 2018 newsletter podcast
In September we updated our listeners on pricing, with our consultation response to the Statutory Regulations scheme proposals. We also discusses PRIME, the EMA’s early access scheme, and changes to our pages on Highly Specialised Technology appraisals in NICE.
August 2018 newsletter podcast – Part 1
There are so many updates to cover this month that the MAP Podcast has been split into two. In the first part we cover updates to PPRS, more on the arrangements around Brexit (specifically a possible implementation period), and guidance from the EU on classification for healthcare apps.
August 2018 newsletter podcast – Part 2
There are so many updates to cover this month that the MAP Podcast has been split into two. In the second part we cover updates to France’s ATU programme for drugs outside of Marketing Authorisation, more on Brexit (NHS staffing, continuity of medical supplies), and the latest on the MAP Conference and the new Member Phoneline.
July newsletter podcast
In July we discussed a set of news articles including new political announcements and a raft of new NHS Commissioning Policies. We introduced the Flexible Pricing scheme under PPRS, gave an update on the 2018 MAP Conference, and described our MAP Tool: International Reference Pricing Lookup Table.
June newsletter podcast
Our June podcast explained the progress on sustainability and transformation partnerships and integrated care systems, several updates to MAP Scotland (e.g. PACS and SMC HTA), further detail on META, and a legal case study around parallel trade in medicine.
May newsletter podcast
April newsletter podcast
PPRS and the new UK statutory regulations – what you need to know!
March newsletter podcast
In this podcast we discuss NICE’s Commissioning Support Process, ATMPs across Europe, Ireland’s revised processes around orphan drugs, reimbursement for MedTech, and the launch of the MedTech Early Technical Assessment (META).